Labs, Payers Don’t Like Prior Authorization for Genetic Tests

By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue

…

Read More

---

Behind-the-Scenes Audits Often Hide Cause of Test Claim Denials

By Virchow | From the Volume XXXI, No. 9 – July 1, 2024 Issue

…

Read More

---

Significant Developments Are Shaping Lab Market

By Robert Michel | From the Volume XXXI, No. 7 – May 20, 2024 Issue

CEO SUMMARY: With 140 speakers and 1,000+ attendees, this year’s Executive War College again provided a comprehensive picture of the specific forces reshaping the U.S. market for lab testing services. Presented here is a smorgasbord of information and innovation shared by different spea…

Read More

---

Artificial Intelligence and Executive War College

By R. Lewis Dark | From the Volume XXXI, No. 6 – April 29, 2024 Issue

By the time you read this our 29th annual Executive W…

Read More

---

Are Lab Leaders Ready for Artificial Intelligence?

By R. Lewis Dark | From the Volume XXXI, No. 5 – April 8, 2024 Issue

WITH ASTONISHING SWIFTNESS, ARTIFICIAL INTELLIGENCE (AI) HAS BECO…

Read More

---

Final Rule on AI Transparency Can Benefit Clinical Labs

By Robert Michel | From the Volume XXXI, No. 5 – April 8, 2024 Issue

ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING are becoming ubiquitous in today’s modern hospital systems and clinical laboratories. In response to these developments, federal officials issued a new rule that has major implications on how healthcare providers use artificial intelligence. T…

Read More

---

Labcorp, Quest Diagnostics Discuss Q4 & 2023 Earnings

By Robert Michel | From the Volume XXXI, No. 4 – March 18, 2024 Issue

DURING RECENT EARNINGS CALLS WITH FINANCIAL ANALYSTS AND INVESTORS, both Labcorp and Quest Diagnostics discussed their fourth quarter (Q4) and full year 2023 financial results. Each reported some stability in the market for clinical laboratory testing services, reflected in the numbe…

Read More

---

Labs Should Prepare for Arrival of ‘Perfect Storm’

By Robert Michel | From the Volume XXXI, No. 3 – February 26, 2024 Issue

CEO SUMMARY: In the near future, clinical labs and pathology groups will need to address three major developments. One involves the FDA proposed LDT rule. A second is the adoption by payers of guidelines that require genetic test claims to have Z-Codes. The third centers around coming ref…

Read More

---

HHS Publishes Final Rule for Health IT Interoperability

By Robert Michel | From the Volume XXXI, No. 3 – February 26, 2024 Issue

THERE IS A NEW FEDERAL RULE intended to improve interoperability and portability of patient information. This rule could be a significant benefit for clinical laboratories and anatomic pathology groups. In December, the US Department of Health and Human Services (HHS) Offi…

Read More

---

Genetic Testing Firm Invitae Files Chapter 11 Bankruptcy, Pursues Sale

By Robert Michel | From the Volume XXXI, No. 3 – February 26, 2024 Issue

INVITAE CORP., A MEDICAL GENETICS COMPANY, got the go ahead in mid-February from the U.S. Bankruptcy Court for the District of New Jersey “to find a buyer and exit from Chapter 11 by late July,” Reuters reported. Invitae said in a news release that it…

Read More

---